Camurus AB is a Swedish biopharmaceutical company that develops and commercializes long-acting medicines for severe and chronic conditions. The company utilizes its proprietary FluidCrystal drug delivery technology to formulate existing active ingredients into extended-release injections, improving patient compliance and treatment outcomes. Its commercial portfolio is primarily focused on treatments for opioid dependence, including its flagship products Buvidal and Brixadi. Camurus also maintains a robust clinical pipeline targeting endocrine diseases, rare diseases, oncology, and pain management. The company operates directly in Europe and Australia, while leveraging strategic partnerships for commercialization in the United States and other global markets.
